Australia's Neuren Pharmaceuticals hits 1-month high on upbeat sales

Neuren Pharmaceuticals

07/11/2024 01:05

** Shares of Neuren Pharmaceuticals  NEU.AX  rise as much as
8.1% to A$14.350, their highest since Oct. 7
    ** Biopharmaceutical reports Rett syndrome drug Daybue's 9
months net sales exceeded full-year threshold of $250 mln
    ** Co sees full-year income to be in the range of A$216 mln
to A$218 mln ($141.83 mln to $143.14 mln)
    ** Stock down 43.1% YTD as of 0046 GMT


($1 = 1.5230 Australian dollars)

 (Reporting by Kumar Tanishk in Bengaluru)
 ((Tanishk.Kumar@thomsonreuters.com))